Yarrow Bioscience (YARW) Long-Term Deferred Tax (2017)

Yarrow Bioscience's (YARW) quarterly Long-Term Deferred Tax came in at $10.4 million in Q4 2017.

Yarrow Bioscience (YARW) Long-Term Deferred Tax (2017) Analysis & Trends

Yarrow Bioscience (YARW) has 1 years of Long-Term Deferred Tax data on file, last reported at $10.4 million in Q4 2017.

Quarterly Long-Term Deferred Tax changed N/A year-over-year to $10.4 million in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $10.4 million (changed N/A YoY) and the FY2017 annual result came in at $10.4 million, changed N/A from the prior year.
Long-Term Deferred Tax was little changed at $10.4 million in Q4 2017.
In the past five years, Long-Term Deferred Tax ranged from a high of $10.4 million in Q4 2017 to a low of $10.4 million in Q4 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Yarrow Bioscience	31.25 Mn	8.33 Mn	-

Download Data

Date	Value
Dec 31, 2017	10.40 Mn